Novo Nordisk has agreed to pay USD 6.3 million to resolve allegations that it violated the False Claims Act by selling items to the United States that were manufactured in non-designated countries.
The settlement resolves allegations that Novo Nordisk violated the Trade Agreements Act, which restricts the procurement of goods under certain government contracts to purchases from specific designated countries, by submitting false claims for payment for medical devices that were manufactured in non-designated countries.
As per US department of Justice, Novo Nordisk sold NovoFine 30G 8 mm needles to United States government agencies from 2012 to 2020 and that from May 2016 through November 2020, Novo Nordisk sold to United States government agencies its NovoFine 32G 6 mm needles, all of which were manufactured in non-designated countries.
